Skip to main content
. 2019 Jan 29;1:100007. doi: 10.1016/j.jvacx.2019.100007

Fig. 2.

Fig. 2

Proportions (%), by risk factor. *Immunocompromised conditions were evaluated at the end of subject’s follow-up. **Subjects were considered immunosuppressed when having at least one period of immunosuppression during their follow-up time.